Inotersen vs placebo
Withdrawals due to adverse events · people with TTR‐FAP
Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 8.57 [1.16, 63.07]1 study · 172 participantsLow